Byetta (Lilly, Exenatide)

DRUG2 trials

Sponsors

Jesper Kjaergaard, Rigshospitalet, Denmark

Conditions

Aortic Valve DiseaseBrain InjuryCardiac ArrestComaCoronary DiseaseRenal FailureShock, CardiogenicStroke

Unknown Phase

GLP-1 Analogs for Neuroprotection After Cardiac Arrest

CompletedNCT02442791

Jesper KjaergaardCardiac Arrest, Coma

Start: 2014-06-30End: 2016-06-30Updated: 2017-09-28

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

Active, not recruitingNCT02673931

Rigshospitalet, DenmarkAortic Valve Disease, Brain Injury, Coronary Disease +3

Start: 2016-02-29End: 2024-09-30Updated: 2024-08-28

Related Papers

Restrictive versus liberal oxygenation in patients undergoing cardiopulmonary bypass-assisted heart surgery: a randomised controlled trial.

2025-09-191 citations

Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial

Circulation Cardiovascular Interventions2025-04-23

Association between inflammatory markers and survival in comatose, resuscitated out-of-hospital cardiac arrest patients

Scandinavian Cardiovascular Journal2022-05-1214 citations

Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial

BMJ Open2021-11-014 citations

Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest

Circulation2016-11-1353 citations

GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial

Trials2016-06-3015 citations